Company / Interest Expense
Aquestive Therapeutics, Inc. Interest Expense History
FY2018-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$6.3M
FY2023
5-year range
$6.3M / $11.1M
FY2019-FY2023
Trend
-3.3%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $11M to $6M over the past 2 years.
Based on SEC 10-K filings.
$6M in FY2023 with a 5-year CAGR of -3.8%.
Improved from $11M to $6M over the past 2 years.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -12.1%
- 5-Year CAGR
- -3.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -3.8%, indicating a declining trend.
- In FY2023, interest expense decreased 3.3% year-over-year.
- Peak interest expense was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $6.3M | -3.3% |
| FY2022 | $6.6M | -40.8% |
| FY2021 | $11.1M | +18.7% |
| FY2020 | $9.3M | +20.8% |
| FY2019 | $7.7M | +0.1% |
| FY2018 | $7.7M | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026